Universal Ibogaine Announces Results of the Annual Meeting of Shareholders

Universal Ibogaine Announces Results of the Annual Meeting of Shareholders

(TheNewswire)

Calgary, AB TheNewswire - September 1 4 2025 Universal Ibogaine Inc. ( TSXV:IBO ) (" UI " or the " Company "), a life sciences company with a mission to research and deliver medicalized ibogaine-centered addiction care, advises of the results of its annual meeting of shareholders (the " Meeting ") which was held in Calgary on September 4, 2025, and of the grant of Restricted Share Units.

Further details of the matters voted on at the Meeting are set out in the Company's Management Information Circular dated July 23, 2025, a copy of which is available on www.sedarplus.ca and was filed on UI's website.   Specific results for the matters voted on at the Meeting are summarized as follows:

  • Election of the Board of Directors (the Board ") – a total of nine nominees (as listed below) were elected to the Company's Board, with each Board member to hold office until the next annual meeting of shareholders or until their successors are duly elected or appointed.

  • Appointment of Auditors - MNP LLP were re-appointed as the auditors of the Company for the next fiscal year at a remuneration to be determined by the Board of Directors.

  • Employee Equity Incentives Plan (the EICP "). The Company's 2025 EICP was not re-approved, as it did not meet the 50% minimum shareholder approval.

  • Stock Option Plan ( SOP ") – the Company's 2024 SOP was not re-approved, as it did not meet the 50% minimum shareholder approval.  The Company intends to study instituting a replacement plan.

Grant of RSUs

UI also advises that, the Board of Directors of the Company previously approved the granting (subject to regulatory approval by the TSX Venture Exchange), effective September 2, 2025, to an Officer of the Company and consultant advisors to the Company, a total of 13,500,000 Restricted Share Units (" RSUs ").  These grant totals include 6,000,000 RSUs Options that were granted to the Company's CEO, Nick Karos.  Entitlement to convert the RSUs into common shares shall vest one year after the date of grant.

Results of AGM

A total of 129,390,665 (41.4%) of the Company's 312,858,516 outstanding common shares were voted at the Meeting.  Specific results for the matters voted on at the Meeting are summarized as follows:

# of

% of

# of votes

% of votes

# of votes

% of votes

votes For

votes For

Withheld

Withheld

Against

Against

Election of the Board of Directors:

Buzunis, Constantine

117,639,065

90.9%

11,751,600

9.1%

n/a

n/a

Cranwill, Ken

117,639,065

90.9%

11,751,600

9.1%

n/a

n/a

Duncan, James

57,312,518

44.3%

72,078,147

55.7%

n/a

n/a

Ginakes, Peter Demos

117,699,865

91.0%

11,690,800

9.0%

n/a

n/a

Hrimech, Eric

57,312,518

44.3%

72,078,147

55.7%

n/a

n/a

Karos, Nick

56,952,517

44.0%

72,438,148

56.0%

n/a

n/a

Killebrew, Nia

57,312,518

44.3%

72,078,147

55.7%

n/a

n/a

Vlahos, Peter

117,239,065

90.6%

12,151,600

9.4%

n/a

n/a

Wagner, Tony

57,312,518

44.3%

72,078,147

55.7%

n/a

n/a

# of

% of

# of votes

% of votes

# of votes

% of votes

votes For

votes For

Withheld

Withheld

Against

Against

Appointment of Auditors

127,668,665

98.7%

1,722,600

1.3%

n/a

n/a

Approval of 2025 EICP

64,090,643

49.5%

n/a

n/a

65,300,022

50.5%

Approval of 2025 SOP

64,090,643

49.5%

n/a

n/a

65,300,022

50.5%

About Universal Ibogaine Inc.

UI is a life sciences company, with a mission to transform addiction treatment using medicalized ibogaine through a planned Canadian clinical trial focused on opioid use disorder(s), and ultimately to utilize that treatment protocol globally through planned future licensing agreements. UI is concurrently developing a state of the art holistic addiction treatment protocol at its Kelburn Recovery Centre (located near Winnipeg, Manitoba) that, which when paired with the planned ibogaine detox protocol, is intended to revolutionize the way we treat addiction and drastically improve the lives of individuals and families affected by addiction.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

‎This news release may contain forward-looking statements and information. Forward-looking information is frequently characterized by words such ‎as "plans", "planned", "expect", "project", "intends", "intended", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI at the date the statements are made.  Although UI believes that the expectations and assumptions on which the forward-‎ looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.

Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎

Additional information identifying risks and uncertainties that could affect financial results and the Company is contained in the Company's filings with Canadian securities regulators, which are available at www.sedarplus.ca

For further information:

Nick Karos, CEO

Universal Ibogaine Inc.

612-309-3527

Nick.Karos@universalibogaine.com

Related Links

https://universalibogaine.com

Copyright (c) 2025 TheNewswire - All rights reserved.

News Provided by TheNewsWire via QuoteMedia

IBO:CA
The Conversation (0)
Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Co-Founder Dr Alberto Sola to Present at upcoming Research to Reality Conference

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform addiction treatment through the use of medicalized ibogaine and a global licensing model is pleased to announce that UI Co-Founder Dr Alberto Sola will... Keep Reading...
UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

UNIVERSAL IBOGAINE RETAINS SHAYNE NYQUVEST AS CAPITAL MARKETS ADVISOR

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has retained Mr. Shayne Nyquvest in a consulting role as Capital Markets Advisor.... Keep Reading...
Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

Universal Ibogaine Advises of Departure of Marilyn Loewen Mauritz from the Board of Directors

(TheNewswire) Calgary, AB TheNewswire - April 21, 2022 Universal Ibogaine Inc. ( TSXV:IBO ) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that Marilyn Loewen Mauritz has resigned as a member of the... Keep Reading...
UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

UNIVERSAL IBOGAINE PROVIDES UPDATE ON KELBURN RECOVERY CENTER OPERATIONS

Universal Ibogaine Inc. (TSXV: IBO) (" UI " or the " Company ") a life sciences company with a mission to develop and deliver medicalized ibogaine-centered addiction care, advises that it has temporarily closed the Kelburn Recovery Centre (" Kelburn ") due to an on-site flooding issue. Kelburn... Keep Reading...
Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Announces Frankfurt Stock Exchange Listing

Universal Ibogaine Inc. (TSXV: IBO) (OTCQB: IBOGF) (FSE: JC4) (" UI " or the " Company ") a life sciences company with a mission to transform the world of addiction treatment through medicalized ibogaine and a state of the art ongoing care program, is pleased to announce that its common shares... Keep Reading...
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...

Latest Press Releases

Related News